Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma
Purpose of Review Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical developmen...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2019-03, Vol.21 (3), p.24-12, Article 24 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 3 |
| container_start_page | 24 |
| container_title | Current oncology reports |
| container_volume | 21 |
| creator | Lattanzi, Michael Balar, Arjun V. |
| description | Purpose of Review
Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development.
Recent Findings
PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. A multitude of ongoing studies are investigating the feasibility and efficacy of incorporating established and novel immunotherapies into earlier lines of therapy, including non-metastatic muscle-invasive bladder cancer and even non-muscle-invasive disease. Early-phase clinical trials have begun to explore the safety and activity of novel immune-oncology combinations across a range of clinical settings.
Summary
Immunotherapy has a clearly defined role in the treatment of metastatic urothelial cancer both in the platinum-refractory setting and in the first-line cisplatin-ineligible setting. Ongoing clinical trials will dictate how to best incorporate immunotherapy into earlier lines of therapy and define the safety and activity of novel immunotherapy agents and combinations. |
| doi_str_mv | 10.1007/s11912-019-0775-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2186149738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2186149738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-8dc987c668000e1e2ae91f0b9fdf79b2df093100a66eebf5b610f7665b7dc4ba3</originalsourceid><addsrcrecordid>eNp1kEFPwyAUx4nROJ1-AC-GxIuX6gNWKEcznS5Z4kF3JrQF7dLSCeWwb29rpyYmnh7k_d4f3g-hCwI3BEDcBkIkoQkQmYAQaZIeoBOSslnCKZeHw5myhAkJE3QawgaAAmRwjCasLzyj7ASt5tF74zr80ukuBqxdiRexi97g-8qboqtah1uLl00TXdu9G6-3O1w5vPbDra50jefaF5VrG32Gjqyugznf1ylaLx5e50_J6vlxOb9bJQUTtEuyspCZKDjPAMAQQ7WRxEIubWmFzGlpQbJ-Qc25MblNc07ACs7TXJTFLNdsiq7H3K1vP6IJnWqqUJi61s60MShKMk5mUrCsR6_-oJs2etf_7osCLmhvbIrISBW-DcEbq7a-arTfKQJqUK1G1apXrQbVapi53CfHvDHlz8S32x6gIxD6lnsz_vfp_1M_AaoNiMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2186067215</pqid></control><display><type>article</type><title>Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma</title><source>SpringerNature Journals</source><creator>Lattanzi, Michael ; Balar, Arjun V.</creator><creatorcontrib>Lattanzi, Michael ; Balar, Arjun V.</creatorcontrib><description>Purpose of Review
Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development.
Recent Findings
PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. A multitude of ongoing studies are investigating the feasibility and efficacy of incorporating established and novel immunotherapies into earlier lines of therapy, including non-metastatic muscle-invasive bladder cancer and even non-muscle-invasive disease. Early-phase clinical trials have begun to explore the safety and activity of novel immune-oncology combinations across a range of clinical settings.
Summary
Immunotherapy has a clearly defined role in the treatment of metastatic urothelial cancer both in the platinum-refractory setting and in the first-line cisplatin-ineligible setting. Ongoing clinical trials will dictate how to best incorporate immunotherapy into earlier lines of therapy and define the safety and activity of novel immunotherapy agents and combinations.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-019-0775-5</identifier><identifier>PMID: 30806823</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Apoptosis ; Bladder cancer ; Cancer therapies ; Cell death ; Chemotherapy ; Cisplatin ; Clinical trials ; Genitourinary Cancers (DP Petrylak and JW Kim ; Immune checkpoint ; Immunotherapy ; Invasiveness ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Oncology ; PD-1 protein ; Platinum ; Section Editors ; Topical Collection on Genitourinary Cancers ; Urothelial cancer ; Urothelial carcinoma</subject><ispartof>Current oncology reports, 2019-03, Vol.21 (3), p.24-12, Article 24</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><rights>Current Oncology Reports is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-8dc987c668000e1e2ae91f0b9fdf79b2df093100a66eebf5b610f7665b7dc4ba3</citedby><cites>FETCH-LOGICAL-c372t-8dc987c668000e1e2ae91f0b9fdf79b2df093100a66eebf5b610f7665b7dc4ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-019-0775-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-019-0775-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30806823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lattanzi, Michael</creatorcontrib><creatorcontrib>Balar, Arjun V.</creatorcontrib><title>Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of Review
Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development.
Recent Findings
PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. A multitude of ongoing studies are investigating the feasibility and efficacy of incorporating established and novel immunotherapies into earlier lines of therapy, including non-metastatic muscle-invasive bladder cancer and even non-muscle-invasive disease. Early-phase clinical trials have begun to explore the safety and activity of novel immune-oncology combinations across a range of clinical settings.
Summary
Immunotherapy has a clearly defined role in the treatment of metastatic urothelial cancer both in the platinum-refractory setting and in the first-line cisplatin-ineligible setting. Ongoing clinical trials will dictate how to best incorporate immunotherapy into earlier lines of therapy and define the safety and activity of novel immunotherapy agents and combinations.</description><subject>Apoptosis</subject><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Genitourinary Cancers (DP Petrylak and JW Kim</subject><subject>Immune checkpoint</subject><subject>Immunotherapy</subject><subject>Invasiveness</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>PD-1 protein</subject><subject>Platinum</subject><subject>Section Editors</subject><subject>Topical Collection on Genitourinary Cancers</subject><subject>Urothelial cancer</subject><subject>Urothelial carcinoma</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kEFPwyAUx4nROJ1-AC-GxIuX6gNWKEcznS5Z4kF3JrQF7dLSCeWwb29rpyYmnh7k_d4f3g-hCwI3BEDcBkIkoQkQmYAQaZIeoBOSslnCKZeHw5myhAkJE3QawgaAAmRwjCasLzyj7ASt5tF74zr80ukuBqxdiRexi97g-8qboqtah1uLl00TXdu9G6-3O1w5vPbDra50jefaF5VrG32Gjqyugznf1ylaLx5e50_J6vlxOb9bJQUTtEuyspCZKDjPAMAQQ7WRxEIubWmFzGlpQbJ-Qc25MblNc07ACs7TXJTFLNdsiq7H3K1vP6IJnWqqUJi61s60MShKMk5mUrCsR6_-oJs2etf_7osCLmhvbIrISBW-DcEbq7a-arTfKQJqUK1G1apXrQbVapi53CfHvDHlz8S32x6gIxD6lnsz_vfp_1M_AaoNiMQ</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Lattanzi, Michael</creator><creator>Balar, Arjun V.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma</title><author>Lattanzi, Michael ; Balar, Arjun V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-8dc987c668000e1e2ae91f0b9fdf79b2df093100a66eebf5b610f7665b7dc4ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Apoptosis</topic><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Genitourinary Cancers (DP Petrylak and JW Kim</topic><topic>Immune checkpoint</topic><topic>Immunotherapy</topic><topic>Invasiveness</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>PD-1 protein</topic><topic>Platinum</topic><topic>Section Editors</topic><topic>Topical Collection on Genitourinary Cancers</topic><topic>Urothelial cancer</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lattanzi, Michael</creatorcontrib><creatorcontrib>Balar, Arjun V.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lattanzi, Michael</au><au>Balar, Arjun V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>21</volume><issue>3</issue><spage>24</spage><epage>12</epage><pages>24-12</pages><artnum>24</artnum><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>Purpose of Review
Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development.
Recent Findings
PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. A multitude of ongoing studies are investigating the feasibility and efficacy of incorporating established and novel immunotherapies into earlier lines of therapy, including non-metastatic muscle-invasive bladder cancer and even non-muscle-invasive disease. Early-phase clinical trials have begun to explore the safety and activity of novel immune-oncology combinations across a range of clinical settings.
Summary
Immunotherapy has a clearly defined role in the treatment of metastatic urothelial cancer both in the platinum-refractory setting and in the first-line cisplatin-ineligible setting. Ongoing clinical trials will dictate how to best incorporate immunotherapy into earlier lines of therapy and define the safety and activity of novel immunotherapy agents and combinations.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30806823</pmid><doi>10.1007/s11912-019-0775-5</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2019-03, Vol.21 (3), p.24-12, Article 24 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2186149738 |
| source | SpringerNature Journals |
| subjects | Apoptosis Bladder cancer Cancer therapies Cell death Chemotherapy Cisplatin Clinical trials Genitourinary Cancers (DP Petrylak and JW Kim Immune checkpoint Immunotherapy Invasiveness Medicine Medicine & Public Health Metastases Metastasis Oncology PD-1 protein Platinum Section Editors Topical Collection on Genitourinary Cancers Urothelial cancer Urothelial carcinoma |
| title | Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T01%3A12%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Status%20and%20Future%20Direction%20of%20Immunotherapy%20in%20Urothelial%20Carcinoma&rft.jtitle=Current%20oncology%20reports&rft.au=Lattanzi,%20Michael&rft.date=2019-03-01&rft.volume=21&rft.issue=3&rft.spage=24&rft.epage=12&rft.pages=24-12&rft.artnum=24&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-019-0775-5&rft_dat=%3Cproquest_cross%3E2186149738%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2186067215&rft_id=info:pmid/30806823&rfr_iscdi=true |